New Horizons in the Treatment and Management of

Atopic Dermatitis (AD): How Novel Therapies are

Changing the Treatment Paradigm

New Horizons in the Treatment and Management of Atopic Dermatitis is a 4-part webcast series that will
provide attendees with the latest information in AD Management.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 4 or in order.

These are archives of live webinars held between February 8, 2017 and March 22, 2017.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

Each session has its own specific valid dates

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the “download” button and either print or save.

This series is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

Description:  Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. Current treatments adequately care for patients with atopic dermatitis, but have shown problems with sustained efficacy in patients with severe eczema or atopic dermatitis. Fortunately for patients with this disease, several new treatments have recently undergone late stage clinical trials that have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life. This activity will focus on the latest clinical data on these evolving options, how clinicians can potentially integrate them into the treatment paradigm, options for patients who have received prior therapies, and information on the mechanisms of action of these agents.

Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin. These treatments have shown the ability to managed the disease in the short term, but have had troubles with long term efficacy. A recent update to the American Academy of Dermatology guidelines of care for the management of adult and pediatric patients recommends a proactive approach for long-term disease management versus episodic management of flares with an emphasis on clinical assessment of disease severity. Several treatments, including novel monoclonal antibodies, have shown the ability in late stage clinical trials to block various proteins that mediate inflammation and immune responses, potentially arresting development and progression of the disease at various pathogenic steps. These new options have shown improved efficacy and safety in atopic dermatitis, and medical directors, practicing physicians, nurses and other healthcare professionals must be educated on these options and how they might affect the current treatment paradigm.

This multi-part program on new horizons and novel therapies in atopic dermatitis will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Attendees will be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients, especially in the area of inadequately controlled moderate-to-severe atopic dermatitis.
 



 
What’s on the Horizon in Atopic Dermatitis (AD): A Closer Look at Integrating Emerging Targeted Therapies into the Treatment Paradigm
  • Explore the mechanism of action in novel therapies in the management of atopic dermatitis
  • Compare and contrast the safety and efficacy of emerging therapies in the management of moderate-to-severe AD
  • Examine recent late stage clinical trial data on novel therapies for patients with moderate-to-severe AD
  • Anticipate challenges for integrating upcoming novel therapies into the treatment paradigm
Physician, Nursing and CMCN credits valid to April 30, 2019
 
Managing Inadequate Response in Moderate-to-Severe AD: Strategies for Patients whose Disease is Not Controlled by Standard Therapy
  • Review strategies for management of patients whose disease is not controlled by standard therapy in moderate to severe AD
  • Analyze challenges clinicians encounter when managing moderate-to-severe AD and discuss evidence-based strategies to overcome these barriers
  • Implement tailored treatment regimens for moderate-to-severe AD that is not controlled based on repeated assessment of disease activity, treatment response, and other patient-specific risks
Physician, Nursing and CMCN credits valid to April 30, 2019
 

Recent Advances in Understanding the Pathogenesis of Atopic Dermatitis

  • Define the research underlying the most current understanding of the pathophysiologic mechanisms of atopic dermatitis
  • Identify the latest research regarding the development of therapeutic agents that address the pathophysiologic mechanisms of atopic dermatitis
  • Discuss the role of emerging therapies that block the IL-4/IL-13 signaling pathway, and how they might be integrated into the evolving treatment paradigm
    What Managed Care Need to Know about Novel Therapies in the Evolving Management of AD
Physician, Nursing and CMCN credits valid to April 30, 2019
 

What Managed Care Need to Know about Novel Therapies in the Evolving Management of AD

  • Discuss methods to enable optimal cost management of emerging therapies to be realized by multiple AD stakeholders including managed care organizations
  • Analyze strategies used by managed care organizations to facilitate high quality care for members with AD, and how newer therapies may affect those strategies
  • Discuss how emerging therapies that are currently undergoing regulatory review and late stage clinical trials will affect managed care professionals in the AD arena if they become available
Physician, Nursing and CMCN credits valid to April 30, 2019